Health
In the 2022/2023 business year, the company’s product portfolio consisted of 653 products

A Decade-Long Commitment to the Treatment of Cancer

We have commemorated World Cancer Day.

More

The continuous operation of Egis is vital

The quality of life of millions depends on the availability of our medicines. Egis is one of the leading generic pharmaceutical companies in Central Easter Europe. We produce approximately 170 million boxes of drugs, 700 tonnes of active pharmaceutical ingredients, 5 billion tablets, capsules annually. Our products are available in 65 countries, and annually more than 30 million patients’ recovery depends on Egis Group’s continuous operation.

More

Wash Your Hands the Right Way

WHO has created a six-step protocol: by applying this method, we can remove the germs, viruses, and bacteria from the surface of our hands.

More

Egis Strengthens European Presence in the Biosimilar Area

Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.

More
WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox